Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU15-223

Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223

Status: Open to Accrual

This is a randomized phase II trial (N=150), comparing the sequence of sunitinib followed by avelumab at progression vs. avelumab followed by sunitinib at progression for patients with metastatic clear cell renal cell carcinoma.

  • Condition: Metastatic renal cell carcinoma
  • Intervention:
    • Drug: Avelumab
    • Drug: Sunitinib
  • Phase: Phase II

For full description, see www.clinicaltrials.gov. (Study #NCT03035630).

Read a news release about this trial.

Project Manager: Michael Nunley, mnunley@hoosiercancer.org; (317) 634-5842, ext. 17.